Origen publishes in Nature a robust and versatile method for creating transgenic chickensJune 08, 2006Origen Therapeutics announced today that it has succeeded in developing a robust and versatile technology for genetically modifying chickens that, for the first time, puts avian transgenics on a par with transgenic mice. The company made the announcement in conjunction with the publication of an article this week by Origen scientists and a collaborator from the University of California, Davis on its transgenic technology in the journal Nature. Using the new technology, Origen can, in principle, make any genetic modification desired to the chicken genome, including the insertion of genetic elements for the production of human therapeutics and the modification of the chicken immune system to produce novel human sequence polyclonal antibodies. Moreover, the new technology opens up the possibility of producing chickens with enhanced agronomic traits, including resistance to avian flu. "This research breakthrough came when we turned our attention to primordial germ cells, the precursor cells to sperm and eggs," said Marie-Cecile van de Lavoir, senior scientist at Origen. "These cells — which we are the first to successfully culture without changing their commitment — proved to be the key to introducing genetic elements into the chicken genome. As a result, we can now take transgene designs that work well in model systems and breed flocks of birds depositing therapeutic proteins in their eggs. The use of primordial germ cells, the ease of producing small or large flocks of chickens, and the existing infrastructure for rearing chickens and processing eggs means that therapeutic proteins can now be produced efficiently and economically in the eggs of chickens." Origen scientists first demonstrated the potential for the production of human protein therapeutics in chicken eggs in August 2005, when company scientists published in Nature Biotechnology the production of human sequence monoclonal antibodies having greatly enhanced cancer killing activity compared to antibodies produced via conventional methods. "While that earlier research was done with chimeric chickens, it demonstrated the enormous opportunities that transgenic chickens hold as a therapeutics production system," said Robert Kay, Ph.D. Origen Therapeutics president and chief executive officer. "We believe a transgenic chicken system offers a number of advantages over either plant or other transgenic animal systems for protein production. Besides the ability to produce antibodies with enhanced cell killing properties, the time from antibody identification to production in eggs is a matter of months, the purification of proteins from eggs is relatively simple, and good manufacturing practices have long been established for vaccine production in chicken eggs. Moreover, the overall cost of facility and operations is a fraction of that associated with fermentation methods of manufacture. The ability to readily create transgenic chickens through this technology, and then to scale up production through conventional breeding further adds to the practicality of this technology for large-scale production of therapeutic proteins." In the early embryo, only a few cells known as primordial germ cells (PGCs) become sperm or eggs in the adult animal. Previous attempts to culture PGCs from mice and humans produced embryonic germ cells that look and act like embryonic stem cells. The chicken is the first species from which PGCs can be isolated, cultured and genetically modified while retaining their commitment to the germ line. Additionally, under certain conditions, Origen scientists could induce the PGCs in vitro to differentiate into embryonic germ cells that contribute to somatic tissue. "As well as the practical applications of this work, the ability to engineer PGCs and influence them to commit in cell culture to either the germline or the somatic lineages provides a very useful new tool for understanding some of the earliest and most fundamental events in developmental biology on a molecular level," said Robert J. Etches, Ph.D., D.Sc., vice president of research at Origen Therapeutics. "This work addresses a major biomedical issue — how to produce antibody-based medicines in an easy, cost-effective way," said Matthew E. Portnoy, Ph.D., of the National Institute of General Medical Sciences, which partially funded the research. "Beyond that, it will help researchers understand stem cell biology and development —something that holds great value for all sorts of basic studies. This is exactly the kind of result we hope for through our Small Business Innovation Research Program." Kureczka/Martin Associates |
|||||||||||||||||||||
| Related Transgenic Current Events and Transgenic News Articles Insect Resistance to Bt Crops can be Predicted, Monitored, and Managed Since 1996, crop plants genetically modified to produce bacterial proteins that are toxic to certain insects, yet safe for people, have been planted on more than 200 million hectares worldwide. UCR plant scientist's research spawns new discoveries showing how crops survive drought Breakthrough research done earlier this year by a plant cell biologist at the University of California, Riverside has greatly accelerated scientists' knowledge on how plants and crops can survive difficult environmental conditions such as drought. Novel mouse gene reduces major pathologies associated with Alzheimer's disease A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). Mouse gene suppresses Alzheimer's plaques and tangles Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. A solution to Darwin's 'mystery of the mysteries' emerges from the dark matter of the genome Biological species are often defined on the basis of reproductive isolation. Ever since Darwin pointed out his difficulty in explaining why crosses between two species often yield sterile or inviable progeny (for instance, mules emerging from a cross between a horse and a donkey), biologists have struggled with this question. Modified crops reveal hidden cost of resistance Genetically modified squash plants that are resistant to a debilitating viral disease become more vulnerable to a fatal bacterial infection, according to biologists. That '4 hour erection': new discovery may help prevent a complication of priapism For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. Wild pigs and deer do not spread GM corn via feces or accumulate transgenic residues in meat Deer stew, roast of wild boar, venison ragout - come fall, all varieties of game are in season for gourmets. However, ever since the worldwide surge in genetically modified corn, critical consumers' appetites have abated somewhat. Alzheimer's researchers find high protein diet shrinks brain One of the many reasons to pick a low-calorie, low-fat diet rich in vegetables, fruits, and fish is that a host of epidemiological studies have suggested that such a diet may delay the onset or slow the progression of Alzheimer's disease (AD). A balancing act in Parkinson's disease: Phosphorylation of alpha-synuclein Both genetic and pathologic data indicate a role for the neuronal protein alpha-synuclein in Parkinson disease. More Transgenic Current Events and Transgenic News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||